**Comprehensive Medical Report**

**Patient Information:**

* Patient ID: [Insert ID]
* Name: [Insert Name]
* Age: 52
* Sex: Male
* Date of Birth: [Insert Date of Birth]

**Medical History:**

* **Primary Diagnosis:** Muscle-invasive bladder cancer (MIBC)
* **Stage and Grade:** T2, high-grade
* **Tumor Characteristics:** High PD-L1 expression
* **Prior Treatments:**
	+ Transurethral resection of the bladder tumor (TURBT)
	+ Cisplatin and gemcitabine chemotherapy
	+ Pembrolizumab immunotherapy
* **Disease Progression:** Recent scans showed disease progression despite above treatments
* **Radiation Therapy:** None to date

**Symptoms and Performance Status:**

* **ECOG Performance Status:** 2 (able to perform basic self-care but with limitations due to fatigue and pelvic pain)
* **Symptoms:**
	+ Persistent fatigue
	+ Mild peripheral neuropathy
	+ Joint pain
	+ Skin rash (from pembrolizumab)
	+ Pelvic pain

**Genetic Testing:**

* **FGFR3 and ERCC2 Mutations:** Not identified
* **PD-L1 Expression:** High
* **Other Genetic Findings:** None reported

**Current Medications:**

* None currently, but patient was recently on pembrolizumab

**Additional Information:**

* **Willingness to Participate in Clinical Trials:** Yes, patient is open to additional testing and willing to participate in clinical trials
* **Availability for Follow-up:** Patient is available for regular follow-up appointments and willing to travel for trial participation if necessary

**Clinical Trial Eligibility:**

* **Eligible for Trials with:** Novel immunotherapies, targeted therapies, or combination regimens
* **Ineligible for Trials with:** FGFR3 or ERCC2 inhibitors (due to lack of mutations)
* **Other Considerations:** Patient's high PD-L1 expression and prior pembrolizumab treatment may impact eligibility for certain trials

This report provides a comprehensive overview of the patient's medical history, current condition, and treatment history. It highlights the patient's willingness to participate in clinical trials and identifies potential eligibility for various trial types.